The HACL1 Knockout Jurkat Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population generated from Jurkat T lymphocytes. Targeted gene disruption at the HACL1 locus yields a heterogeneous pool of edited cells harboring diverse loss-of-function alleles, providing a population-level model that minimizes clonal bias. This polyclonal format is especially suited for pooled phenotypic screens, biochemical characterizations, and studies where functional heterogeneity mirrors biological complexity. By avoiding monoclonal selection, researchers can examine integrated responses to HACL1 loss across a varied genetic backdrop.
Jurkat cells are an immortalized human CD4+ T lymphocyte line originally isolated from an acute T cell leukemia patient. They grow in suspension and are extensively employed to dissect T cell receptor signaling, cytokine production, apoptosis, and HIV infection mechanisms. The line??s well-defined NF-??B, NFAT, and MAPK signaling frameworks, combined with homogeneous suspension culture and robust proliferation, offer an ideal platform for repeatable immune-cell assays and scalable biochemical analyses.
HACL1 encodes 2-hydroxyacyl-CoA lyase, a thiamine pyrophosphate-dependent peroxisomal enzyme that mediates the carbon-carbon bond cleavage of 2-hydroxyacyl-CoA substrates. Its canonical reaction converts 2-hydroxyphytanoyl-CoA into pristanal and formyl-CoA, a pivotal step in the alpha-oxidation of phytanic acid. Transcriptionally upregulated by PPAR-alpha, HACL1 acts downstream of phytanoyl-CoA hydroxylase (PHYH) and upstream of fatty aldehyde dehydrogenase (ALDH3A2) within the peroxisomal alpha-oxidation complex. The reaction products enter beta-oxidation pathways, giving rise to medium-chain fatty acids, diverse acyl-CoA species, and NADH, thereby linking HACL1 activity to broader lipid metabolic networks and cellular redox balance.
Within Jurkat T cells, peroxisomal fatty acid metabolism increasingly appears as a modulator of immune function, where alpha-oxidation defects can disturb membrane lipid composition, signal transduction, and stress resilience. HACL1 disruption enables the study of phytanic acid accumulation and altered 2-hydroxy fatty acid degradation on T cell receptor signaling, activation marker expression, and cytokine profiles. This model provides an immunologically relevant system for investigating Refsum disease and related peroxisomopathies, offering the ability to correlate metabolic perturbations with T cell activation, proliferation, and apoptosis using established Jurkat-based assays.
Researchers can validate HACL1 knockout via western blotting, RT-qPCR, and peroxisomal immunofluorescence, while functional alpha-oxidation impairment is measurable by GC-MS quantification of phytanic acid levels. Flow cytometric detection of activation markers such as CD69 and CD25 following phytanic acid challenge, along with cell viability assays under lipid stress, reveal metabolic vulnerabilities. Lipidomics profiling of medium-chain fatty acids and acyl-CoA pools further defines metabolic reprogramming. These applications position the HACL1 Knockout Jurkat Polyclonal Cells as a versatile resource for exploring peroxisomal fatty acid oxidation, Refsum disease mechanisms, and the intersection of lipid metabolism with T cell biology. For technical inquiries or ordering, contact Ascent Research.
